share_log

BRII-B Covid Combination Therapy Retains Neutralizing Activity against Omicron

AASTOCKS ·  Jul 27, 2022 04:50
BRII-B (02137.HK) announced new live virus data confirming that the amubarvimab/ romlusevimab combination, a long-acting COVID-19 monoclonal antibody therapy, retains
neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.
The U.S. Food and Drug Administration is currently reviewing the Company's Emergency Use Authorization application for the amubarvimab/ romlusevimab combination.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment